%0 Journal Article
%T A Sudden Onset of Severe Thrombocytopenia While Using Evolocumab
%A Ikegami
%A Yuichi
%A Inoue
%A Ikuo
%A Kin
%A Yoshitora
%A Saito
%A Daigo
%A Shimada
%A Akira
%A Takenaka
%A Yasuhiro
%A Yamazaki
%A Satoshi
%J -
%D 2020
%R https://doi.org/10.1155/2020/3281626
%X A 72-year-old man with a 10-year history of coronary heart disease started evolocumab treatment once a month after developing excess myalgia due to therapy with a 3-hydroxy-methylglutaryl CoA reductase inhibitor. No side effects such as myalgia symptoms had been reported during the first 14 months of evolocumab treatment; however, he suddenly presented with acute severe thrombocytopenia following the 14th treatment. His platelet count continued to decrease to a nadir of 1,000/¦ÌL. His platelet-associated immunoglobulin G level had elevated to 790£¿ng/107£¿cells. He started receiving a combination of steroid therapy, high-dose immunoglobulin therapy, and platelet transfusions, but the first-line therapy was ineffective. He was subsequently treated with a thrombopoietin receptor agonist, and his platelet count recovered to 250,000/¦ÌL
%U https://www.hindawi.com/journals/crihem/2020/3281626/